ASCO 2023 | Promising TKI-ICI combinations for non-clear cell RCC
Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the promising results of combining tyrosine kinase inhibitors (TKIs) with immune checkpoint inhibitors (ICIs) for non-clear cell renal cell carcinoma (RCC). Initially, there were concerns about the effectiveness of these combinations, but recent studies with cabozantinib plus nivolumab and lenvatinib plus pembrolizumab have shown high levels of activity, indicating the potential for tyrosine kinase inhibitors beyond VEGF inhibition. These findings highlight the importance of exploring new treatment approaches for non-clear cell kidney cancer, offering hope for improved outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
